Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review

BACKGROUND: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradox...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Zheng, Zeng, Yue-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Atopic Dermatitis – Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407831/
https://www.ncbi.nlm.nih.gov/pubmed/37100035
http://dx.doi.org/10.1159/000530608
_version_ 1785086050065973248
author Su, Zheng
Zeng, Yue-Ping
author_facet Su, Zheng
Zeng, Yue-Ping
author_sort Su, Zheng
collection PubMed
description BACKGROUND: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradoxical cutaneous reaction associated with biologics. SUMMARY: This is a scoping review in order to summarize the demographics and epidemiology, clinical manifestations, diagnosis, potential pathogenesis, and promising management of dupilumab-associated psoriasis and psoriasiform manifestations.
format Online
Article
Text
id pubmed-10407831
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-104078312023-08-09 Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review Su, Zheng Zeng, Yue-Ping Dermatology Atopic Dermatitis – Review Article BACKGROUND: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradoxical cutaneous reaction associated with biologics. SUMMARY: This is a scoping review in order to summarize the demographics and epidemiology, clinical manifestations, diagnosis, potential pathogenesis, and promising management of dupilumab-associated psoriasis and psoriasiform manifestations. S. Karger AG 2023-04-26 2023-08 /pmc/articles/PMC10407831/ /pubmed/37100035 http://dx.doi.org/10.1159/000530608 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Atopic Dermatitis – Review Article
Su, Zheng
Zeng, Yue-Ping
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title_full Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title_fullStr Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title_full_unstemmed Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title_short Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
title_sort dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review
topic Atopic Dermatitis – Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407831/
https://www.ncbi.nlm.nih.gov/pubmed/37100035
http://dx.doi.org/10.1159/000530608
work_keys_str_mv AT suzheng dupilumabassociatedpsoriasisandpsoriasiformmanifestationsascopingreview
AT zengyueping dupilumabassociatedpsoriasisandpsoriasiformmanifestationsascopingreview

Ejemplares similares